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STUDY QUESTION:What is the impact of cancer in females aged ≤39 years on subsequent chance of pregnancy?
SUMMARY ANSWER: Cancer survivors achieved fewer pregnancies across all cancer types, and the chance of achieving a ﬁrst pregnancy
was also lower.
WHAT IS KNOWN ALREADY: The diagnosis and treatment of cancer in young females may be associated with reduced fertility but the
true pregnancy deﬁcit in a population is unknown.
STUDY DESIGN, SIZE, DURATION:We performed a retrospective cohort study relating ﬁrst incident cancer diagnosed between 1981
and 2012 to subsequent pregnancy in all female patients in Scotland aged 39 years or less at cancer diagnosis (n = 23 201). Pregnancies were
included up to end of 2014. Females from the exposed group not pregnant before cancer diagnosis (n = 10 271) were compared with general
population controls matched for age, deprivation quintile and year of diagnosis.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Scottish Cancer Registry records were linked to hospital discharge records to
calculate standardized incidence ratios (SIR) for pregnancy, standardized for age and year of diagnosis. Linkage to death records was also per-
formed. We also selected women from the exposed group who had not been pregnant prior to their cancer diagnosis who were compared
with a matched control group from the general population. Additional analyses were performed for breast cancer, Hodgkin lymphoma, leu-
kaemia, cervical cancer and brain/CNS cancers.
MAIN RESULTS AND THE ROLE OF CHANCE: Cancer survivors achieved fewer pregnancies: SIR 0.62 (95% CI: 0.60, 0.63). Reduced
SIR was observed for all cancer types. The chance of achieving a ﬁrst pregnancy was also lower, adjusted hazard ratio = 0.57 (95% CI: 0.53,
0.61) for women >5 years after diagnosis, with marked reductions in women with breast, cervical and brain/CNS tumours, and leukaemia.
The effect was reduced with more recent treatment period overall and in cervical cancer, breast cancer and Hodgkin lymphoma, but was
unchanged for leukaemia or brain/CNS cancers. The proportion of pregnancies that ended in termination was lower after a cancer diagnosis,
and the proportion ending in live birth was higher (78.7 vs 75.6%, CI of difference: 1.1, 5.0).
LIMITATIONS, REASONS FOR CAUTION: Details of treatments received were not available, so the impact of speciﬁc treatment regi-
mens on fertility could not be assessed. Limited duration of follow-up was available for women diagnosed in the most recent time period.
WIDER IMPLICATIONS OF THE FINDINGS: This analysis provides population-based quantiﬁcation by cancer type of the effect of can-
cer and its treatment on subsequent pregnancy across the reproductive age range, and how this has changed in recent decades. The
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demonstration of a reduced chance of pregnancy across all cancer types and the changing impact in some but not other common cancers
highlights the need for appropriate fertility counselling of all females of reproductive age at diagnosis.
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Introduction
Continuing advances in therapy mean that many girls and young women
can now expect long-term survival following a diagnosis of cancer, and
thus there exists a rapidly increasing population of survivors of childhood
and young adulthood cancer (Skinner et al., 2006). Increasing importance
is therefore placed on the quality of their survivorship and their risk of ‘late
effects’ from their successful treatment (Oefﬁnger et al., 2006; Armstrong
et al., 2016). The possible impact on fertility is one of the consequences of
cancer treatment of greatest importance to patients (Peate et al., 2009).
The adverse effects of cancer treatment on fertility in both men and
women have been recognized for many years, and the importance and
establishment of fertility preservation as part of current medical practice is
recognized in international guidelines (Loren et al., 2013; National
Institute for Clinical Excellence, 2013). What is less clear, however, is the
overall extent of post-cancer loss of fertility within a population, as investi-
gation of this issue has often focused on speciﬁc diagnoses or otherwise
selected patient groups (Bramswig et al., 2015; Armuand et al., 2017).
The US Childhood Cancer Survivors Study (CCSS), which is based on
self-reported questionnaires, has provided detailed analyses of fertility and
pregnancy outcomes in relation to diagnosis and treatment using siblings
as controls (Signorello et al., 2006; Green et al., 2009; Chow et al., 2016).
However, this and the British Childhood Cancer Survivors Study (BCCSS)
(Reulen et al., 2009) are conﬁned to those diagnosed before the age of 21
and 15 years respectively, with limited data on the extent of reduced fer-
tility and pregnancy outcome in unselected populations (Chiarelli et al.,
1999; Clark et al., 2007; Winther et al., 2009a; Haggar et al., 2014).
Additionally, studies of reproductive function in adult women have often
used amenorrhoea or premature ovarian insufﬁciency (POI) as the key
outcome (Swerdlow et al., 2014; Jacobson et al., 2016) which may not
closely reﬂect the experience of failure to conceive in these patients
(Letourneau et al., 2012; Barton et al., 2013), additionally impacted by
social, psychological and sexual effects of cancer and its treatment (Ganz
et al., 1998; Howard-Anderson et al., 2012).
In Scotland, the availability of linkable databases of cancer registrations
and pregnancy-related outcome records offers the opportunity to study
whether women achieve pregnancy after a cancer diagnosis on a popu-
lation basis.
Materials andMethods
Study population
Female patients with a record of a ﬁrst incident cancer diagnosed below
the age of 40 years between 1981 and 2012 in Scotland were identiﬁed
from the Scottish Cancer Registry and linked to national general and
maternity hospital discharge records to ascertain subsequent pregnancies
(miscarriage, termination of pregnancy, or delivery of a still or live born
infant) up until the end of 2014. Linkage to subsequent death records up
to the end of 2014 was also performed (see Supplementary Information
Tables S1–S3 for ICD codes). Record linkage involved deterministic match-
ing based on the Community Health Index (CHI) number, a unique identify-
ing number used on all patient records in Scotland. Individuals were assigned
to population-weighted ﬁfths of deprivation scores (Morris and Carstairs,
1991) by applying 1991 and 2001 census-derived scores to the periods of
diagnosis 1981–1995 and 1996–2012, respectively. This is based on small
area of residence, and is derived from four variables collected at each decen-
nial census: social class, unemployment, overcrowding and car ownership.
Patients treated with radiotherapy and with chemotherapy in the ﬁrst 2
years following the cancer incidence date from 1997 onwards were identiﬁed
from Scottish Cancer Registry records; prior to 1997, acute hospital discharge
records were used to identify any radiotherapy or chemotherapy treatments
(see Supplementary Information Tables S1–S3). As these records do not con-
tain all episodes of radiotherapy or chemotherapy treatment, any patients
with no matching treatment records were recorded as Not Known.
Ethical approval
The study was approved by the Privacy Advisory Committee of the
National Health Service National Services Scotland—study reference num-
ber XRB13215.
Standardized incidence ratio of subsequent
pregnancy for all women with cancer
We compared the total number of pregnancies in the exposed group after
cancer diagnosis to the number expected based on pregnancy rates in the
general population from the date of cancer incidence to the date of death
or 31 December 2014, whichever occurred ﬁrst. Indirectly standardized
incidence ratios (SIR) of pregnancy were calculated, standardized for age,
deprivation quintile and calendar year of diagnosis. Pregnancy rates for the
general population were calculated using mid-year population estimate
denominator data sourced from National Records of Scotland. The overall
impact of each cancer diagnostic group was calculated from the number of
women with each diagnosis and its impact, as a proportion of the total
pregnancy deﬁcit.
Subsequent ﬁrst pregnancy for women
nulliparous at cancer diagnosis
The second part of the study selected only women from the exposed
group who had not been pregnant before their cancer diagnosis (or within
6 months of the date of cancer diagnosis to ensure exclusion of women
diagnosed during pregnancy). Data on previous pregnancies were available
from 1981 onwards. An unexposed control group, similarly required to
have had no pregnancy outcome events before or within 6 months of the
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Table I Standardized incidence ratio for subsequent pregnancy in all women with cancer onset at age ≤39 years,
1981–2012.
Women with cancer Pregnancies following cancer
Number % Observed Expected SIR* 95% CI
Lower Upper
Total 23201 100.0 6627 10736 0.62 0.60 0.63
Type of cancer
Colorectal 589 2.5 98 185 0.53 0.43 0.64
Liver 63 0.3 11 11 0.96 0.48 1.71
Bone 236 1.0 99 156 0.63 0.52 0.77
Skin (melanoma/non-melanoma) 5252 22.6 2563 2949 0.87 0.84 0.90
Connective and soft tissue 333 1.4 126 177 0.71 0.59 0.85
Breast 5173 22.3 547 1404 0.39 0.36 0.42
Cervix uteri 3498 15.1 552 1611 0.34 0.31 0.37
Ovary 1129 4.9 415 658 0.63 0.57 0.69
Kidney 237 1.0 56 90 0.62 0.47 0.81
Eye 122 0.5 31 66 0.47 0.32 0.67
Brain, CNS 1045 4.5 208 497 0.42 0.36 0.48
Thyroid 926 4.0 499 636 0.79 0.72 0.86
Hodgkin lymphoma 962 4.1 585 870 0.67 0.62 0.73
Non-Hodgkin lymphoma 673 2.9 217 323 0.67 0.58 0.77
Leukaemia 1077 4.6 235 494 0.48 0.42 0.54
Other 1886 8.1 385 608 0.63 0.57 0.70
Age at cancer diagnosis (years)
0–14 1638 7.1 561 778 0.72 0.66 0.78
15–24 2674 11.5 2052 2984 0.69 0.66 0.72
25–29 3378 14.6 1906 2821 0.68 0.65 0.71
30–34 5926 25.5 1493 2693 0.55 0.53 0.58
35–39 9585 41.3 615 1459 0.42 0.39 0.46
Deprivation category at cancer diagnosis
1—Least deprived 4671 20.1 1338 2161 0.62 0.59 0.65
2 4451 19.2 1278 1875 0.68 0.64 0.72
3 4690 20.2 1314 2098 0.63 0.59 0.66
4 4760 20.5 1429 2231 0.64 0.61 0.67
5—Most deprived 4629 20.0 1268 2371 0.53 0.51 0.56
Period of cancer onset
1981–1988 4628 19.9 1294 2422 0.53 0.51 0.56
1989–1996 5765 24.8 1780 3280 0.54 0.52 0.57
1997–2004 6323 27.3 2184 3303 0.66 0.63 0.69
2005–2012 6485 28.0 1369 1732 0.79 0.75 0.83
Record of chemotherapy
Yes 6274 27.0 1010 2110 0.48 0.45 0.51
No 7107 30.6 2642 3235 0.82 0.79 0.85
Not known 9820 42.3 2975 5391 0.55 0.53 0.57
Record of radiotherapy
Yes 4557 19.6 655 1525 0.43 0.40 0.46
No 8538 36.8 2862 3587 0.80 0.77 0.83
Not known 10106 43.6 3110 5624 0.55 0.53 0.57
*Standardized for age, deprivation and calendar year of cancer diagnosis; follow up from date of cancer incidence to death or 31 December 2014.
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matching date, was created from the general population using the CHI
database which includes all patients registered with a General Practitioner
in Scotland. Controls were matched on age, deprivation quintile and year
of cancer diagnosis. For exposed patients diagnosed between 1981 and
1997, the deprivation category of controls as at 1997 was used for match-
ing because address details before 1997 (required to assign deprivation
status) were not known. Three controls were selected for every member
of the exposed group. Of the 30 813 controls, two were subsequently
removed from the analysis due to incorrect linkage.
The primary outcome was the ﬁrst pregnancy event (miscarriage, ter-
mination or delivery) occurring at least 6 months after the date of cancer
incidence, or the corresponding date in matched controls. We also exam-
ined the proportions of pregnancies ending in miscarriage, termination, still
birth or live birth, as well as the still birth and infant death rates.
Cumulative incidence curves were produced for each cancer type show-
ing the cumulative incidence of ﬁrst pregnancy and, separately, death over
follow up time for the exposed cases and the controls (Scrucca et al.,
2007). Because mortality was an important competing risk, Fine and Gray
competing risk models (Fine and Gray, 1999) were used to calculate sub-
distribution hazard ratios (HRs) and 95% CI for pregnancy. Four models
were run to examine variations in the association between cancer and
pregnancy by (i) duration of follow-up time (since hazards were not pro-
portional over time); (ii) age group at diagnosis of cancer; (iii) deprivation
quintile; and (iv) period of diagnosis of cancer. Both unadjusted HRs and
HRs adjusted for age group at diagnosis, deprivation quintile, period of
diagnosis and cancer type as appropriate were produced.
Three further models were run: (i) HRs for pregnancy for the different
cancer types relative to the entire control group controlling for other fac-
tors. (ii) An extension of this model including an interaction term between
period of diagnosis and cancer type to generate adjusted HRs by period of
diagnosis for pre-speciﬁed cancer types of interest: leukaemia, Hodgkin
lymphoma, breast, cervical and brain/CNS cancers. (iii) To examine the
effect of treatment, run on a subset of the exposed group who were diag-
nosed from 1997 onwards and whose treatment could therefore be estab-
lished from Scottish Cancer Registry records. The small number of
patients for whom the treatment received was recorded as unknown were
excluded from this analysis. All models were run in Stata version 14 MP
(StataCorp LP, College Station, TX, USA). Model assumptions were
checked by splitting follow-up time into three periods and comparing HRs
during these periods.
Results
All pregnancies following cancer diagnosis
This analysis included 23 201 women aged 39 or younger at time of
cancer diagnosis (Supplementary Information Table S4). Overall the
cancer survivors achieved a lower than expected number of pregnan-
cies compared to the general population of women: 6627 observed
compared to 10 736 expected pregnancies, SIR 0.62 (95% CI: 0.60,
0.63: Table I). Thus cancer survivors were approximately 38% less likely
to achieve pregnancy after diagnosis. SIR was signiﬁcantly reduced for
women with all cancer types with the exception of liver cancer, which
was the least prevalent. SIR ranged from 0.34 (0.31–0.37) for women
with cervical cancer, to 0.87 (0.84–0.90) for skin cancers (Table I). The
contribution of diagnostic groups to the overall pregnancy deﬁcit (Fig. 1)
shows that cervical and breast cancer accounted for 26 and 21% of the
pregnancy deﬁcit, respectively, with additional substantial contributions
(6–9% of the total deﬁcit) from skin cancer, brain/CNS cancers, Hodgkin
lymphoma and leukaemia.
SIR was signiﬁcantly reduced across all age at diagnosis and depriv-
ation groups, and there were clear effects of both chemotherapy and
radiotherapy (Table I). SIR varied strongly by period of cancer diagno-
sis, being lower for women with cancer diagnosed in the earlier peri-
ods: 0.53 (0.51, 0.56) for women diagnosed 1981–1988 compared to
0.79 (0.75, 0.83) for women diagnosed in 2005–2012. Skin cancer
became much more frequent over the period of analysis (Table I): on
reanalysis after excluding skin cancers, overall SIR was further reduced
to 0.52 (0.51, 0.54), however, the effect of period was still very
apparent.
First ever pregnancies following cancer
diagnosis
This analysis included 10 271 women aged 39 or younger who were
nulliparous at the time of their cancer diagnosis and 30 811 matched
controls (Supplementary Information Table S5). The cumulative inci-
dence of ﬁrst pregnancy after cancer was markedly reduced, with
overall adjusted HR = 0.57 (95% CI: 0.53, 0.61) for those with >5
years follow-up (Table II and Fig. 2). Adjusted HR was reduced for all
diagnostic groups, showing similar general patterns to the SIR analysis
with marked impacts of cancers of the cervix (0.22), brain/CNS (0.18)
and leukaemia (0.21). Cumulative incidence of subsequent ﬁrst preg-
nancy for these diagnoses and for breast cancer and Hodgkin lymph-
oma (Fig. 2) highlight the very different patterns of subsequent
pregnancy compared to age matched controls after these diagnoses
(results for other diagnoses are shown in Fig. 3). The impact of previ-
ous cancer on subsequent pregnancy was signiﬁcant for women diag-
nosed in each age group, with the oldest age group showing a slightly
reduced impact (Table II). There were no differences by deprivation
category.
As in the SIR analysis, the impact of cancer was much less for
women diagnosed in more recent periods, despite possible limitations
of shorter follow up with more recent diagnosis. Among women diag-
nosed with cancer in 1981–1988, adjusted HR for subsequent ﬁrst
1,059
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Skin
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Leukaemia
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Non-Hodgkin lymphoma
Colorectal
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259
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Figure 1 The impact of speciﬁc cancer diagnoses on the overall
pregnancy deﬁcit. The data shown are the differences between the
number of pregnancies expected and those observed for each diag-
nostic group over the period of this study, represented graphically as
a proportion of the total pregnancy deﬁcit. Thus women with cervical
cancer aged up to 39 had 1059 fewer pregnancies than matched con-
trols over the period 1984–2014, which was 26% of the total preg-
nancy deﬁcit.
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Table II Hazard ratio for subsequent ﬁrst pregnancy in nulliparous women with cancer onset at age ≤39 years,
1981–2012.
Hazard ratio
Unadjusted 95% CI Adjusted 95% CI
Lower Upper Lower Upper
Duration of follow up following cancer diagnosis (1)
<1 year 0.13 0.11 0.15 0.12 0.10 0.14
1–4 years 0.41 0.39 0.44 0.36 0.34 0.39
≥5 years 0.79 0.74 0.85 0.57 0.53 0.61
Cancer type (2)
Colorectal 0.28 0.19 0.40 0.26 0.18 0.38
Liver 0.36 0.17 0.78 0.27 0.12 0.60
Bone 0.49 0.37 0.65 0.30 0.22 0.39
Skin (melanoma and non-melanoma) 0.84 0.78 0.90 0.66 0.62 0.72
Connective and soft tissue 0.39 0.30 0.52 0.25 0.19 0.34
Breast 0.20 0.17 0.23 0.30 0.26 0.35
Cervix uteri 0.25 0.21 0.30 0.22 0.18 0.26
Ovary 0.53 0.44 0.62 0.37 0.31 0.45
Kidney 0.34 0.24 0.50 0.33 0.23 0.47
Eye 0.24 0.14 0.42 0.21 0.12 0.37
Brain, CNS 0.24 0.20 0.30 0.18 0.15 0.22
Thyroid 1.03 0.89 1.20 0.69 0.59 0.81
Hodgkin lymphoma 0.91 0.81 1.02 0.46 0.40 0.52
Non-Hodgkin lymphoma 0.47 0.38 0.59 0.34 0.28 0.43
Leukaemia 0.28 0.23 0.33 0.21 0.17 0.25
Other 0.28 0.23 0.34 0.27 0.22 0.32
Age at cancer diagnosis (years) (3)
0–14 0.39 0.36 0.42 0.37 0.34 0.39
15–24 0.37 0.33 0.41 0.37 0.33 0.41
25–29 0.38 0.35 0.42 0.36 0.33 0.40
30–34 0.39 0.35 0.44 0.39 0.35 0.44
35–39 0.52 0.44 0.62 0.53 0.44 0.63
Deprivation category at cancer diagnosis (4)
1—Least deprived 0.45 0.40 0.50 0.37 0.34 0.41
2 0.47 0.43 0.53 0.40 0.36 0.44
3 0.44 0.39 0.49 0.36 0.33 0.40
4 0.47 0.42 0.51 0.38 0.35 0.42
5—Most deprived 0.45 0.41 0.50 0.37 0.33 0.41
Period of cancer diagnosis (5)
1981–1988 0.30 0.27 0.33 0.20 0.18 0.22
1989–1996 0.40 0.37 0.44 0.34 0.31 0.37
1997–2004 0.63 0.58 0.69 0.61 0.56 0.67
2005–2012 0.63 0.57 0.70 0.62 0.56 0.69
Chemo/radiotherapy status (6)
Chemotherapy only 0.38 0.32 0.45 0.43 0.34 0.53
Radiotherapy only 0.57 0.45 0.74 0.66 0.50 0.86
Chemo and radiotherapy 0.30 0.24 0.37 0.36 0.29 0.47
Models based on 10 271 women with cancer and 30 811 general population controls except for chemo/radiotherapy effects: these models based on 2619 women with cancer receiving chemo/
radiotherapy and 2473 not receiving chemo/radiotherapy. Follow up from date of cancer/matching to ﬁrst pregnancy, death or 31 December 2014.
(1) Hazard ratios relative to controls with same duration of follow-up.
(2) Hazard ratios relative to matched controls for each cancer type.
(3) Hazard ratios relative to controls of same age.
(4) Hazard ratios relative to controls of same deprivation category.
(5) Hazard ratios relative to controls matched in that period.
(6) Hazard ratios relative to patients with cancer who did not undergo chemotherapy or radiotherapy.
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pregnancy was 0.20 (0.18, 0.22) compared with 0.62 (0.56, 0.69) in
women diagnosed in 2005–2012. Analysis of the effect of period of
diagnosis revealed marked increases in adjusted HR for subsequent
ﬁrst pregnancy in more recent periods for breast cancer, Hodgkin
lymphoma and cervical cancer (Fig. 4), with in the latter case women
diagnosed in the most recent period showing no signiﬁcant effect on
subsequent ﬁrst pregnancy (HR = 0.88 (0.68, 1.14)). There was a very
different pattern for leukaemia and brain/CNS cancers (Fig. 4), with
adjusted HRs remaining very low across all diagnostic periods.
The proportion of ﬁrst singleton pregnancies after cancer that ended
in a termination was lower among women with previous cancer (with
analysis by age at diagnosis showing this was signiﬁcant in all age groups
except the oldest) and the proportion ending in a live birth was corres-
pondingly higher (Table III). The proportion of pregnancies achieved
that ended in miscarriage or still birth was similar, as was the infant
death rate for live births.
Discussion
This analysis provides robust, population-based evidence for the effect
of cancer and its treatment on subsequent pregnancy in women aged
under 40 at the time of diagnosis. There was an overall reduction in
the likelihood of pregnancy after diagnosis of 38% compared to the
general population, with a comparable reduction in the incidence of
ﬁrst pregnancy after cancer. The reduction was seen in all groups by
age at diagnosis and across the diagnostic spectrum, even in cancers
which are predominantly managed surgically, although treatment with
chemotherapy and radiotherapy were both shown to have important
effects. There was no marked variation by deprivation index.
The clear reduction in overall impact on subsequent pregnancy by
treatment period showed marked differences by diagnosis. The strik-
ing change for women with cervical cancer is likely to reﬂect changes in
both the detection and treatment of early stages of cervical cancer,
with widespread screening introduced in the 1980s, and the current
development of fertility-sparing surgery (Rob et al., 2011). Hodgkin
lymphoma and breast cancer also showed improvement in chance of
ﬁrst pregnancy after cancer with more recent diagnosis. This improve-
ment is in keeping with recent data (Bramswig, et al., 2015) showing
limited overall impact of Hodgkin lymphoma in girls on the proportion
subsequently achieving parenthood (although abdominal radiotherapy
was associated with substantial reduction) and shows parallels to over-
all reductions in secondary mortality in Hodgkin lymphoma and other
childhood cancers, associated with reductions in the use of radiother-
apy (Armstrong, et al., 2016). The impact of breast cancer and its
Figure 2 Cumulative probability of ﬁrst pregnancy after cancer diagnosis (red) in all women with cancer compared to population controls (blue),
and in women with breast, cervical, brain/CNS cancers, Hodgkin lymphoma and leukaemia. Tables under each panel indicate the number of women
with cancer and controls at the time of diagnosis, and at subsequent time points up to 30 years.
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treatment may be augmented by prolonged adjuvant endocrine ther-
apy in hormone-sensitive disease (Shandley et al., 2017), with the con-
sequent reduction in fertility due to increasing age being of substantial
importance, and concern over the potential impact of pregnancy on
the risk of recurrence (Azim et al., 2013).
In marked contrast leukaemia and brain/CNS cancers showed no
improvement in the chance of subsequent ﬁrst pregnancy over the 30-
year period of analysis. Bone marrow transplantation (BMT) remains
the most effective treatment for leukaemia in young people excluding
children (Sellar et al., 2011; Rowe, 2013), and our ﬁndings reﬂect the
high risk of loss of fertility associated with total body irradiation or high
dose alkylating agent based chemotherapy as conditioning treatment
before BMT for acute leukaemia (Salooja et al., 2001). For brain
tumours effective treatments such as cranio-spinal radiotherapy can
impact on later reproductive function (Bath et al., 2001). Survivors of
brain/CNS cancer may also have a signiﬁcant neurocognitive
Figure 3 Cumulative probability of ﬁrst pregnancy after cancer diagnosis (red) in women with diagnoses other than those shown in Fig. 2 compared
to population controls (blue). Tables under each panel indicate the number of women with cancer and controls at the time of diagnosis, and at subse-
quent time points up to 30 years.
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impairment (Ellenberg et al., 2009) and are less likely to be married or
cohabiting (Frobisher et al., 2007; Koch et al., 2011), illustrating some
of the range of factors that impact on the likelihood of post-cancer
pregnancy. Choosing not to have a (further) pregnancy after cancer,
i.e. not to complete a previously intended family size, may also have an
impact. This may underlie the effect of cancers which are largely mana-
ged surgically, such as skin cancers, and would not be expected to
have an adverse effect on the reproductive system.
Reassuringly, our results show no increased risk of miscarriage or
still birth among ﬁrst pregnancies achieved after a cancer diagnosis.
The slightly lower proportion of pregnancies among women with pre-
vious cancer that end in a termination of pregnancy may reﬂect more
active planning of pregnancies in the cancer group, increased use of
contraception, or continuation of more unplanned pregnancies: fur-
ther research is needed to identify which of these factors have a role.
Infant death following a live birth was uncommon in both the cancer
and control groups, with no evidence of increased risk among the off-
spring of women with cancer. Although the present data show no
reduction in the chance of live birth after cancer, previous studies have
indicated that cancer survivors are at risk of a range of pregnancy
complications including miscarriage, premature delivery and low birth
weight, particularly associated with radiotherapy to a ﬁeld that includes
the pelvis for childhood cancer (Clark, et al., 2007; Winther et al.,
2008; Reulen, et al., 2009; Signorello et al., 2010; Haggar, et al., 2014;
Reulen et al., 2017). The ﬁnding of a reduced prevalence of termin-
ation of pregnancy differs from a Danish analysis (Winther et al.,
2009b); this may reﬂect both the size of the present analysis, and the
accurate recording of this outcome.
The varied and changing but still reduced chance of pregnancy in
young female survivors of cancer demonstrated here means that it
remains important to identify those girls and women at signiﬁcant risk
to offer timely access to fertility preservation treatments (Anderson
et al., 2015). These include oocyte vitriﬁcation in postpubertal women,
although this requires ovarian stimulation, with signiﬁcant time implica-
tions (Argyle et al., 2016; Lavery et al., 2016), or cryopreservation of
ovarian tissue which has no lower age limit but requires a surgical inter-
vention and may risk re-introducing malignant cells (Loren, et al.,
2013). Appropriate longer term follow-up for those young females at
risk of a reduced chance of a pregnancy after successful treatment of
their primary cancer remains important (Scottish Intercollegiate
Guidelines Network, 2013). Reproductive counselling, diagnosis and
treatment of POI and access to assisted reproductive technologies
should be a priority for young female cancer survivors who are
deemed to be at high risk of a reduced chance of pregnancy (Wallace
et al., 2012).
The largest datasets on pregnancy after cancer come from studies of
childhood cancer survivors, with little comparable data from women
diagnosed in adulthood. The CCSS has provided benchmark studies
demonstrating this risk (Sklar et al., 2006; Green, et al., 2009) although
it is not population based. The relative risk for female survivors of ever
being pregnant was 0.81 compared with siblings (Green, et al., 2009),
and a more recent analysis reported a hazard ratio for pregnancy of
0.87 in females who had been treated with chemotherapy but not
radiotherapy to the brain or pelvis (Chow, et al., 2016). The BCCSS
(Reulen, et al., 2009) also reported that the number of live births
observed from all female survivors was two-thirds of that expected,
though that analysis is limited to girls aged under 15 years at diagnosis.
A recent population based Swedish cohort study (Armuand, et al.,
2017) of 552 female survivors of cancer in childhood or adolescence
(<21 years) who were born between 1973 and 1977 showed that the
Figure 4 Adjusted HR (with 95% CI) for ﬁrst pregnancy after can-
cer diagnosis by period of diagnosis for women with breast, cervical,
Hodgkin lymphoma, leukaemia and brain/CNS cancers.
............................. ............................. ..........................
.............................................................................................................................................................................................
Table III Outcomes of singleton ﬁrst pregnancies among nulliparous women with cancer onset at age ≤39 years,
Scotland, 1981–2012 and matched controls.
Singleton ﬁrst pregnancies following cancer
onset/matching date to 31 December 2014
Nulliparous women
with cancer
Control women Difference 95% CI
Number %/rate* Number %/rate* Lower Upper
Total 2071 100 11772 100
Miscarriage 203 9.8 1095 9.3 0.5 −0.9 1.9
Termination 231 11.2 1725 14.7 −3.5 −5.0 −2.0
Still birth 8 0.4 53 0.5 −0.1 −0.4 0.2
Live birth 1629 78.7 8899 75.6 3.1 1.1 5.0
Infant death 12 7.4 43 4.8 2.5 −1.9 6.9
*% of all ﬁrst singleton pregnancies apart from for infant deaths which is per 1000 live births.
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HR for ﬁrst live birth was 21% lower than for controls, with particular
effects of CNS tumours and leukaemia. Our study, includes all girls and
women diagnosed with cancer without potentially biased incomplete
or selective follow-up and includes those who have received radiother-
apy to a ﬁeld that includes the brain or pelvis. This suggests a greater
impact with adjusted HR of 0.37 for girls and young women in both
the under 15 years and 15–24 age group. The present analysis now
provides for the ﬁrst-time robust analysis of the effect of cancer on the
likelihood of a pregnancy, and of a ﬁrst pregnancy, after all cancer diag-
noses in girls and adult women, up to the age of 39.
While major strengths of this analysis are its size and unbiased,
population based data, and the inclusion of women up to age 39,
weaknesses include the necessarily short duration of follow-up of
those most recently diagnosed, and the lack of detailed treatment
information. The effect of cancer was conﬁrmed here to be most
marked in the early years after diagnosis, so the HR for those diag-
nosed in the most recent period will be a conservative analysis.
Treatment information is at present not routinely collected in the
national databases used in this study, but is important to allow more
precise analysis of the effects of components of treatment regimens on
fertility. The relative contributions of diagnosis/treatment related loss
of fertility and psychological and social factors such as concerns over
cancer recurrence and other health issues (Schover, 2005; Howard-
Anderson, et al., 2012; Nilsson et al., 2014) are unclear. Information
on early miscarriage is also likely to be incomplete, as the data only
include miscarriages managed in a hospital setting, but this is likely to
affect data from cancer survivors equally to the general population.
In conclusion, this study shows the impact of cancer on the subse-
quent chance of pregnancy, both overall and of ﬁrst pregnancy, in girls
and women. A reduction in the chance of ﬁrst pregnancy was seen
across all ages at diagnosis and widely across diagnostic groups. We
clearly show that the impact of cancer on the chance of subsequent
pregnancy in young women is much <20–30 years ago for some key
diagnoses but remains present, and there has been no improvement in
the impact on later pregnancy of other diagnoses, notably leukaemia
and brain/CNS cancer. These data quantify the impact of cancer on
subsequent pregnancy. They highlight the need for interventions to
protect fertility in girls and young women with cancer at the time of
diagnosis and to support women considering pregnancy once treat-
ment is completed.
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